Nephrotic syndrome diff way of approach
Reading File
Finding Sources
Searching PubMed
"nephrotic syndrome" differential diagnosis management
Reading File
Reading File
Finding Sources
Reading File
Finding Sources
Reading File
Finding Sources
Reading File
Reading File
Finding Sources
Reading File
Finding Sources
Reading File
Finding Sources
Reading File
I now have rich content from Brenner & Rector's The Kidney and Comprehensive Clinical Nephrology. Let me now compile the full, structured differential approach to nephrotic syndrome.
Nephrotic Syndrome: Differential Approach
1. Definition and Core Features
Nephrotic syndrome is defined by the tetrad:
- Proteinuria >3.5 g/day (adults) or >40 mg/m²/hr (children)
- Hypoalbuminaemia (<3 g/dL)
- Oedema (periorbital, dependent, ascites, pleural effusion)
- Hyperlipidaemia and lipiduria (oval fat bodies, fatty casts)
Additional metabolic consequences include hypercoagulability, immune deficiency (loss of IgG and complement), hormonal imbalances (loss of thyroid-binding globulin, transferrin), and diuretic resistance.
2. Approach 1 - By Age (Practical Clinical Framework)
This is the most useful bedside framework, since the most likely cause is strongly age-dependent.
| Age Group | Most Likely Cause | Comment |
|---|---|---|
| Infants (<1 yr) | Congenital nephrotic syndrome (Finnish type, diffuse mesangial sclerosis) | Genetic - autosomal recessive; biopsy required |
| Children 1-8 yr | Minimal Change Disease (MCD) - 70-90% | Empirical steroid trial; biopsy if atypical |
| Children >8 yr | MCD still common; FSGS increasing | Consider biopsy earlier |
| Young adults | FSGS, MCD, IgA nephropathy | Biopsy usually required |
| Adults 30-60 yr | Membranous Nephropathy (MN) most common primary cause | Check anti-PLA2R; rule out secondary causes |
| Elderly >60 yr | MN (paraneoplastic), amyloidosis, diabetic nephropathy | Screen for malignancy; check SPEP/UPEP |
- Brenner and Rector's The Kidney - FSGS now accounts for 17% of glomerulonephritides in Caucasians and is rising; collapsing FSGS is disproportionately common in African Americans.
3. Approach 2 - Primary vs. Secondary Causes
Primary (Idiopathic) Glomerular Diseases
| Disease | Key Features | EM Findings | IF |
|---|---|---|---|
| Minimal Change Disease (MCD) | Most common in children; selective proteinuria; normal light microscopy | Diffuse foot process effacement | Negative |
| FSGS | Nephrotic + non-nephrotic; rising incidence; APOL1 risk in African Americans | Foot process effacement; focal sclerosis | Negative (primary) |
| Membranous Nephropathy (MN) | Commonest primary NS in adults; thickened GBM; "spike and dome" | Subepithelial deposits | IgG4, C3 granular |
| MPGN pattern | Nephrotic + nephritic overlap; low complement | Mesangial + subendothelial deposits | IgG, IgM, C3 |
| IgA Nephropathy | Usually haematuria, can have nephrotic component | Mesangial deposits | IgA dominant |
| C1q Nephropathy | Young patients; steroid-resistant | - | C1q mesangial |
Secondary Causes (Box 31.1, Brenner & Rector)
Drugs and chemicals:
- Mercury, gold, penicillamine → Membranous pattern
- NSAIDs → MCD or MN
- Heroin → FSGS (collapsing variant)
- Lithium → MCD or FSGS
- Pamidronate, interferon-alpha → FSGS
- Captopril → MN
Infections:
- Hepatitis B → MN (especially in children, Asia)
- Hepatitis C → MPGN, cryoglobulinaemia
- HIV-1 → Collapsing FSGS (HIVAN)
- Syphilis (secondary/congenital) → MN
- Malaria (quartan, P. malariae) → MPGN
- Schistosomiasis, filariasis, trypanosomiasis → MPGN/MN pattern
Systemic diseases (Multisystem):
- Diabetes mellitus → Diabetic nephropathy (most common worldwide secondary cause)
- SLE → Lupus nephritis (Class V = pure MN pattern)
- Amyloidosis (AL, AA) → Congo red positive; apple-green birefringence
- Rheumatoid arthritis → Amyloidosis (AA) or gold/penicillamine MN
- Mixed connective tissue disease, dermatomyositis
Malignancies:
- Hodgkin lymphoma → MCD (classic association via T-cell cytokines)
- Solid tumors (lung, colon, breast, stomach) → MN (paraneoplastic)
- CLL, multiple myeloma (amyloidosis) → various patterns
- Waldenström macroglobulinaemia
Hereditary/Genetic:
- Alport syndrome → progressive haematuria + proteinuria; GBM thinning/lamellation on EM
- Congenital nephrotic syndrome (NPHS1-nephrin, NPHS2-podocin mutations)
- Denys-Drash syndrome (WT1 mutation)
- Fabry disease (alpha-galactosidase A deficiency)
Miscellaneous:
- Preeclampsia
- Morbid obesity (secondary FSGS via hyperfiltration/glomerulomegaly)
- Sickle cell disease, cyanotic congenital heart disease
- Vesicoureteric reflux nephropathy
- Renal artery stenosis
4. Approach 3 - By Histological Pattern (Biopsy-Based)
This is used after biopsy to narrow the secondary cause search:
| Biopsy Pattern | Primary Cause | Key Secondary Causes to Exclude |
|---|---|---|
| Normal LM, foot process effacement on EM | MCD | NSAIDs, Hodgkin lymphoma, lithium, atopy |
| Focal segmental sclerosis | Primary FSGS | HIV, heroin, obesity, reflux, reduced nephron mass, Pamidronate |
| Thickened GBM, "spikes" on silver stain | MN | HBV, SLE (Class V), malignancy, drugs (gold, penicillamine) |
| Mesangial + subendothelial deposits, MPGN pattern | MPGN | HCV/cryoglobulinaemia, SLE, complement disorders, monoclonal Ig |
| Amyloid (Congo red +) | AL or AA amyloidosis | Myeloma, RA, chronic infection, IBD |
| Mesangial IgA | IgA nephropathy | Henoch-Schönlein purpura, liver disease |
5. Approach 4 - By Selectivity of Proteinuria
Historically used to predict cause and steroid response, though now superseded by biopsy:
- Highly selective proteinuria (albumin >> IgG loss; selectivity index <0.1): Suggests MCD - likely steroid-responsive
- Non-selective proteinuria: Suggests FSGS, MN, or secondary cause - less likely steroid-responsive
6. Approach 5 - Clinical Clues and Associations
| Clue | Think of |
|---|---|
| Child 1-8 yr + no haematuria + normal BP | MCD - empirical steroids before biopsy |
| Steroid-resistant NS in child | FSGS (podocin/NPHS2 mutation), MN |
| NS + haematuria | FSGS, MPGN, lupus nephritis, IgA |
| NS + low complement (C3, C4) | SLE, MPGN, cryoglobulinaemia, postinfectious GN |
| NS + diabetic retinopathy | Diabetic nephropathy (biopsy may be deferred) |
| NS + elderly + no retinopathy in diabetic | Biopsy - may be MN or amyloid, not diabetic nephropathy |
| NS + anti-PLA2R positive | Primary MN (70% of idiopathic MN) |
| NS + SPEP with M-spike | AL amyloidosis or monoclonal Ig deposition disease |
| NS + HIV + African American | Collapsing FSGS (HIVAN) |
| NS + HBV | MN (especially in children) |
| NS + HCV + purpura + low C4 | Cryoglobulinaemic MPGN |
| NS + Hodgkin's lymphoma | MCD |
| NS + solid tumor in >50 yr | Paraneoplastic MN |
| NS + family history | Alport syndrome, congenital NS (nephrin/podocin) |
| NS + deafness + ocular abnormalities | Alport syndrome (COL4A3/4/5 mutations) |
7. Approach 6 - Complications (to guide urgency)
All nephrotic patients must be assessed for:
| Complication | Mechanism | Clinical implication |
|---|---|---|
| Hypercoagulability | Loss of antithrombin III, protein S; elevated fibrinogen, V, VIII, X | DVT, renal vein thrombosis (especially MN), pulmonary embolism - anticoagulate if albumin <2 g/dL or evidence of thrombosis |
| Infection | Loss of IgG, complement (factor B, C3, C1q); oedema as culture medium | Spontaneous bacterial peritonitis (Streptococcus pneumoniae), pneumococcal vaccine recommended |
| AKI | Volume depletion (underfill in MCD), thrombosis, diuretic overuse | Check FEna; MCD = contracted volume + activated RAAS; others = expanded volume + suppressed RAAS |
| Hyperlipidaemia | Increased hepatic VLDL synthesis; decreased lipoprotein lipase | Increased atherosclerotic risk; treat with statins |
| Hypothyroidism | Loss of thyroid-binding globulin | Check TFTs |
| Iron-deficiency | Loss of transferrin | |
| Growth failure | In children with prolonged NS |
- Brenner and Rector's The Kidney, pp. 2277-2278 (edema mechanisms), p. 1338 (classification), pp. 1342-1347 (MCD, FSGS pathogenesis)
- Comprehensive Clinical Nephrology, 7th Edition (FSGS, MN, MPGN mechanisms)
8. When to Biopsy
Biopsy can be deferred if:
- Child aged 1-8 years with typical nephrotic syndrome (no haematuria, normal complement, normal BP, no hypertension) → empirical steroid trial first
Biopsy is indicated if:
- Adult with new nephrotic syndrome
- Child with atypical features (haematuria, hypertension, low complement, steroid resistance)
- Suspicion of secondary cause requiring specific treatment
- Elderly patient with NS to exclude malignancy-related MN or amyloid
- Diabetic patient without retinopathy or with atypical course
Quick Summary Mnemonic
"MCD - FSGS - MN - MPGN" in order of frequency by age:
- Minimal change - Children
- FSGS - Young adults/African Americans
- Membranous - Middle-aged adults
- MPGN - Any age + low complement
Secondary causes: think DANISH - Drugs, Amyloid/Autoimmune, Neoplasm, Infection, Systemic (DM, SLE), Hereditary
Wht is th definition of nephrotic syndrome according to ispad guidelines 2025
Searching the Web
IPNA 2025 nephrotic syndrome definition guidelines children
Searching PubMed
"nephrotic syndrome" children guidelines definition IPNA 2025
Reading Web Page
definition nephrotic syndrome proteinuria hypoalbuminemia criteria IPNA KDIGO 2025
A quick clarification first: there are no "ISPD 2025" guidelines for nephrotic syndrome - ISPD (International Society for Peritoneal Dialysis) deals with dialysis, not nephrotic syndrome. You likely mean IPNA (International Pediatric Nephrology Association) and/or KDIGO 2025 guidelines. The 2025 KDIGO guideline explicitly harmonizes its definitions with IPNA. Here is the complete, sourced answer:
Nephrotic Syndrome Definition - KDIGO 2025 / IPNA (Harmonized)
The 2025 KDIGO Clinical Practice Guideline for the Management of Nephrotic Syndrome in Children aligns all definitions with the IPNA clinical practice recommendations (Trautmann et al., Pediatric Nephrology 2023 for SSNS; 2020 for SRNS).
Definition of Nephrotic Syndrome
Nephrotic syndrome (NS) = Nephrotic-range proteinuria PLUS either:
- Hypoalbuminaemia (serum albumin <30 g/L / 3 g/dL), OR
- Oedema (when albumin level is not available)
Definition of Nephrotic-Range Proteinuria (KDIGO 2025 - expanded from 2021)
| Method | Threshold |
|---|---|
| Spot urine protein-to-creatinine ratio (UPCR) | ≥200 mg/mmol (≥2 g/g) |
| 24-hour urine protein | ≥1000 mg/m²/day |
| Urine dipstick | 3+ (300-1000 mg/dL) or 4+ (≥1000 mg/dL) |
The 2025 update expanded this definition to include additional testing strategies for more granularity compared to the 2021 version (which only used first morning or 24h PCR ≥2 g/g or ≥3+ dipstick).
Key Associated Definitions (KDIGO 2025 / IPNA Harmonized)
| Term | Definition |
|---|---|
| Complete remission | First morning or 24h UPCR ≤200 mg/g (≤20 mg/mmol) OR negative/trace dipstick - on ≥3 consecutive days |
| Partial remission | UPCR >200 mg/g but <2 g/g (>20 but <200 mg/mmol) AND serum albumin ≥30 g/L |
| Relapse | Recurrence of nephrotic-range proteinuria in a child who had previously achieved complete remission - dipstick ≥3+ for 3 consecutive days |
| SSNS | Complete remission within 4 weeks of standard-dose prednisolone (note: 2025 changed "after" to "within") |
| SRNS | No complete remission after 4-6 weeks of standard glucocorticoid therapy |
| Infrequent relapse | <3 relapses in any 12-month period (2025: lowered from <4 in 2021) |
| Frequent relapse (FRNS) | ≥3 relapses in any 12-month period |
| Steroid-dependent (SDNS) | 2 consecutive relapses during steroid taper or within 2 weeks of stopping |
| "Confirmation period" | New in 2025 - the 4-6 week window where children with only partial response at 4 weeks get 2 additional weeks + RAS blockade to confirm sensitivity vs. resistance |
Important Notes
-
The guideline applies to children aged 1-18 years. Children under 1 year fulfilling NS criteria must be referred to a pediatric nephrologist, as management of that age group is beyond this guideline's scope.
-
The "confirmation period" is a new 2025 concept - if a child has only partial response at 4 weeks (not complete remission), 2 more weeks with continued glucocorticoids + RAS blockade are given before labelling them steroid-resistant. This prevents over-classifying late responders as SRNS.
-
The relapse definition was refined in 2025: it now specifically requires prior complete remission before a recurrence counts as a relapse (absent in 2021).
-
Infrequent relapse threshold was lowered from <4 to <3 relapses/year, bringing KDIGO in line with IPNA.
Sources:
- KDIGO 2025 Clinical Practice Guideline for Nephrotic Syndrome in Children, Kidney International 107(Suppl 5S), 2025
- IPNA Clinical Practice Recommendations - Trautmann A et al., Pediatric Nephrology 2023;38:877-919 (SSNS) and 2020;35:1529-1561 (SRNS)
- ERA Immunonephrology Working Group commentary, PMC12789865
Give me in short...just the exact defination
Based on the KDIGO 2025 / IPNA harmonized definition:
Nephrotic Syndrome =
Nephrotic-range proteinuria (UPCR ≥200 mg/mmol or ≥1000 mg/m²/day or dipstick 3+/4+) + Serum albumin <30 g/L OR oedema (if albumin unavailable)
That's the exact, complete definition.
This is a shared conversation. Sign in to Orris to start your own chat.